 - For the endocrine resistant cohort: Ki67 10 by central testing at Washington University AMP laboratory from a tumor biopsy performed after at least 2 weeks on neoadjuvant endocrine therapy. Note that prior neoadjuvant endocrine therapy could include any endocrine therapy including aromatase inhibitor, tamoxifen, fulvestrant alone or in combination, or endocrine therapy in combination with any investigational agent that is not a Cdk 46 inhibitor 